- ►diabetesjournals.org M Blüher, S Engeli, N Klöting, J Berndt, M … - Diabetes, 2006 - Am Diabetes Assoc The endocannabinoid system has been suspected to contribute to the association
of visceral fat accumulation with metabolic diseases. We determined whether
circulating endocannabinoids are related to visceral adipose tissue mass in ... Cited by 128 - Related articles - BL Direct - All 8 versions
M Cote, I Matias, I Lemieux, S Petrosino, N … - International Journal of Obesity, 2007 - nature.com Plasma 2-AG, but not AEA, levels correlated positively with BMI, waist girth,
IAA measured by computed tomography, and fasting plasma triglyceride and insulin
levels, and negatively with high-density lipoprotein cholesterol and ... Cited by 75 - Related articles - BL Direct - All 4 versions
- ►endojournals.org I Matias, MP Gonthier, P Orlando, V Martiadis … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Cannabinoid CB 1 receptor blockade decreases weight and
hyperinsulinemia in obese animals and humans in a way greatly independent from
food intake. ... Objective: The objective of this study was to ... Cited by 171 - Related articles - BL Direct - All 7 versions
S Engeli, J Böhnke, M Feldpausch, K … - Diabetes, 2005 - Am Diabetes Assoc Obesity is the main risk factor for the development of type 2 diabetes.
Activation of the central endocannabinoid system increases food intake and
promotes weight gain. Blockade of the cannabinoid type 1 (CB-1) receptor ... Cited by 211 - Related articles - BL Direct - All 12 versions
P Juan-Picó, E Fuentes, F Javier Bermudez- … - Cell Calcium, 2006 - Elsevier Insulin is the main hormone involved in the regulation of glycaemia, its
impaired secretion is a hallmark of type I and type II diabetic individuals.
Additionally, insulin is involved in lipogenesis and weight gain, provoking ... Cited by 88 - Related articles - All 4 versions
- ►nih.gov D Osei-Hyiaman, M DePetrillo, P Pacher, J Liu … - Journal of Clinical Investigation, 2005 - Am Soc Clin Investig Endogenous cannabinoids acting at CB 1 receptors stimulate appetite, and CB 1
antagonists show promise in the treatment of obesity. CB 1 –/– mice are
resistant to diet-induced obesity even though their caloric intake is ... Cited by 391 - Related articles - All 13 versions
YL Liu, IP Connoley, CA Wilson, MJ Stock - International Journal of Obesity, 2004 - nature.com To investigate the effect of SR141716, a selective CB1 receptor antagonist, on
energy expenditure and on glucose uptake in isolated soleus muscle of Lep ob
/Lep ob mice. ... Female Lep ob /Lep ob mice (8–10 weeks old) were ... Cited by 171 - Related articles - All 4 versions
R Roche, L Hoareau, S Bes-Houtmann, MP … - Histochemistry and cell biology, 2006 - Springer Abstract To investigate the expression of the endoc- annabinoid 1 and 2
receptors by human adipocyte cells of omental and subcutaneous fat tissue, as
well as to determine whether these receptors are functional. The expression ... Cited by 61 - Related articles - All 6 versions
- ►aspetjournals.org M Bensaid, M Gary-Bobo, A Esclangon, JP … - Molecular pharmacology, 2003 - ASPET This study investigates the effects of SR141716, a selective CB 1 receptor
antagonist that reduces food intake and body weight of rodents, on Acrp30 mRNA
expression in adipose tissue. Acrp30, a plasma protein exclusively ... Cited by 364 - Related articles - BL Direct - All 5 versions
